Jointown Pharmaceutical Group (600998) Q1 2026 earnings summary

Executive summary

• Achieved revenue of RMB 44.78 billion in Q1 2026, up 6.58% year-over-year, with core distribution and emerging businesses driving growth.

• Net profit attributable to shareholders was RMB 733 million, down 24.41% year-over-year due to lower non-recurring gains compared to last year.

• Excluding non-recurring items, net profit attributable to shareholders rose 7.12% year-over-year to RMB 543 million.

• Cash flow from operating activities improved by 9.15% year-over-year, with stronger sales collections.

Financial highlights

• Operating income: RMB 44.78 billion, up 6.58% year-over-year.

• Net profit attributable to shareholders: RMB 733 million, down 24.41% year-over-year.

• Basic and diluted EPS: RMB 0.14, down 26.32% year-over-year.

• Total assets at quarter-end: RMB 121.72 billion, up 4.57% from year-end 2025.

• Net cash flow from operating activities: -RMB 3.02 billion, improved from -RMB 3.33 billion last year.

Outlook and guidance

• Management expects full-year operating cash flow to turn positive, matching business performance, as receivables collection intensifies in Q4.